US FDA recommends approval for Astellas' Cresemba to treat invasive ...
... treatment of invasive aspergillosis, and 8 to 2 with one abstention to recommend approval for the treatment of invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients.
pharmabiz.com - Mon, 26 Jan 2015 21:26

FDA Committee Recommends Antifungal Treatment Approval
Pharmacy Times - Mon, 26 Jan 2015 06:15



Astellas' Novel Anti-Fungal Wins FDA Panel Support
Mucormycosis, also known as zygomycosis, is triggered by fungi found on dead leaves and decaying wood. It is an uncommon infection, but it is "one of the most life-threatening mold infections in patients with hematologic malignancies and in ...
MedPage Today - Fri, 23 Jan 2015 09:03

Cresemba Approval Supported by FDA Advisory Committee
Monthly Prescribing Reference - Thu, 22 Jan 2015 13:02

FDA Recommends Approval of Astellas' Fungal Infection Treatment
... treatment of invasive aspergillosis, and 8 to 2 with one abstention to recommend approval for the treatment of invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients.
Drug Discovery & Development - Thu, 22 Jan 2015 11:41

FDA Advisory Panel to Review Novel Antifungal Drug
Mucormycosis, also known as zygomycosis, is triggered by fungi found on dead leaves and decaying wood. Risk factors of infection include uncontrolled diabetes, cancer, organ transplant, a low white blood cell count, and skin trauma. According to the ...
MedPage Today - Wed, 21 Jan 2015 15:26

Basilea announces that FDA's Anti-Infective Drugs Advisory Committee ...
... the treatment of invasive aspergillosis, and eight to two with one abstention to recommend approval for the treatment of invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in ...
Virtual-Strategy Magazine (press release) - Thu, 22 Jan 2015 12:03

Astellas' Isavuconazonium Should Pass Ad Comm Meeting For 2 Indications ...
Although less common than aspergillosis, mucormycosis (also called zygomycosis) is deadlier. Mucormycosis spreads throughout the body in 23% of cases; when that happens, there is 97% certainty of death if appropriate treatment can't be found. Therefore ...
Seeking Alpha - Wed, 21 Jan 2015 05:30



FDA panel gives thumbs-up to Astellas/Basilea antifungal
The second vote was 8 to 2 (with one abstention) to back the drug for treatment of invasive mucormycosis, also known as zygomycosis. The two are life-threatening fungal infections predominantly occurring in immunocompromised patients. Astellas expects ...
PharmaTimes - Thu, 22 Jan 2015 15:37

FDA drug approvals-January 2015
Isavuconazonium (Cresemba, Astellas) once-daily intravenous and oral braod-spectrum for the treatment of invasive aspergillosis, invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in ...
ModernMedicine - Fri, 09 Jan 2015 11:38


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014